Tag: Tezacaftor

Approved by the FDA on December 20, 2024, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a once-daily, triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for patients aged 6 and older who have specific genetic mutations. This medication builds upon previous advancements to offer a more convenient dosing schedule and enhanced efficacy for eligible individuals.

Traditionally, cystic fibrosis (CF) has been managed with treatments that address symptoms rather than the underlying cause. The emergence of Trikafta has revolutionized this approach, providing a targeted therapy that directly addresses the defective protein, significantly improving lung function and overall health for many with CF.

More than 90% of cystic fibrosis (CF) patients in the United States are eligible for treatment with Trikafta. So, what class of drug is Trikafta? It belongs to a revolutionary class of medications known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, specifically a triple-combination therapy, that directly targets the underlying genetic cause of the disease.